by the ORP. This feature highlights an NCCN study funded through the grant mechanism. Randomized Phase II Trial of Osimertinib With or Without Local Consolidation Therapy for Patients With EGFR-Mutant Metastatic Non–Small Cell Lung Cancer (NORTHSTAR
Search Results
Highlights of the NCCN Oncology Research Program
Oncology Research Program
by the ORP. This feature highlights an NCCN study funded through the grant mechanism. Randomized Phase II Trial of Osimertinib With or Without Local Consolidation Therapy for Patients With EGFR -Mutant Metastatic Non–Small Cell Lung Cancer (NORTHSTAR
Highlights of the NCCN Oncology Research Program
by the ORP. This feature highlights an NCCN study funded through the grant mechanism. Randomized Phase II Trial of Osimertinib With or Without Local Consolidation Therapy for Patients With EGFR-Mutant Metastatic Non–Small Cell Lung Cancer (NORTHSTAR
CLO24-086: The Effect of TBI-Based Conditioning Regimen on Recurrence and Transplant-Related Mortality Among Patients With Mantle Cell Lymphoma Who Received Autologous Bone Marrow Transplant
Yanal Alnimer, Feviz F. Yalniz, Chaitanaya Iragavarapu, Reshma Ramlal, Reinhold Munker, Ayman Qasrawi, and Gregory Monohan
Introduction: Autologous bone marrow transplant (ASCT) is the standard consolidation therapy for eligible mantle cell lymphoma (MCL) patients. BEAM is widely used as a conditioning regimen. Here-in, we used the CIBMTR data to evaluate the role
BPI22-024: Assessing the Adherence to Standard of Care With Durvalumab and Overcoming Barriers in the Treatment of Unresectable Stage III Non-Small Cell Lung Cancer: A Single Institution Retrospective Study
Madhulika Urella, Jai Kumar Khatri, Anwar Khurram, Vivek Yadala, Adarsh Sidda, Noman Jang Khan, and Maria Tria Tirona
chemoradiotherapy. The National Comprehensive Cancer Network (NCCN) has added consolidative therapy with Durvalumab for patients with Stage III NSCLC following definitive concurrent chemoradiation treatment as a category 1 recommendation. Durvalumab is a human IgG1
CLO21-022: Efficacy and Safety Outcomes With Therapies for Stage I-III Merkel Cell Carcinoma (MCC): A Systematic Literature Review
David Miller, Roberto Palencia, Ting Yu, Amrita Sandhu, Sarah Webb, Tom Blaikie, and Murtuza Bharmal
), neoadjuvant, and maintenance/consolidation therapies after SUR were included. First, 2 reviewers independently reviewed titles and abstracts for eligibility. Second, the full text of all selected titles were reviewed. Discrepancies were reconciled by an
Newly Diagnosed Multiple Myeloma: How Many Drugs Are Enough?
Presented by: Shaji K. Kumar
administered induction therapy, consolidation therapy with autologous stem cell transplant (ASCT), and maintenance therapy with one or more drugs. For those who are transplant-ineligible, the phases of treatment are not as clear—patients are often continued on
Treatment of Acute Promyelocytic Leukemia for Older Patients
Thomas Prebet and Steven D. Gore
magnesium), which may represent an important issue in older patients. During treatment, the authors recommend close monitoring of EKG and serum biochemistry (once or twice a week), with early electrolyte replacement if needed. Consolidation Therapy
The Role of Myeloid Growth Factors in Acute Leukemia
Martha Wadleigh and Richard M. Stone
, double-blind, placebo-controlled, phase III study of filgrastim in remission induction and consolidation therapy for adults with de novo acute myeloid leukemia. The International Acute Myeloid Leukemia Study Group . Blood 1997 ; 90 : 4710 – 4718
Postconsolidation Maintenance and Monitoring in Patients With Acute Promyelocytic Leukemia
Chezi Ganzel, Dan Douer, and Martin S. Tallman
’s leukocyte count. Consolidation therapy included 3 different regimens with several combinations of mitox, DNR, etoposide, Ara-C, and IDA. Randomization was between intensified maintenance or none. The maintenance consisted of different combinations of drugs
